Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
NCT01790594 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE2 · terminated · last registry update 2026-09-24 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual within enrollment time period: projected accrual goal not achieved.” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision